All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

Germany's aap Implantate Q3 revenue rises on US growth

By Reuters News


Overview

  • Germany medical device maker's Q3 revenue rose 2% yr/yr to EUR 3.3 mln

  • Company's U.S. business grew 2% in local currency in Q3

  • EBITDA for first nine months stayed above break-even, reflecting operational improvements


Outlook

  • Company expects to further reduce cumulative revenue shortfall in Q4

  • aap sees progress and additional growth in APAC in Q4

  • Company began Q4 with highest monthly order intake of the year in U.S.


Result Drivers

  • U.S. GROWTH - Co said U.S. business grew 2% in local currency in Q3, building on a strong prior-year quarter

  • EMEA RECOVERY - Revenue in EMEA region rose 3% in Q3, with significant recovery in the Middle East and new product growth in Spain and Portugal

  • LATAM STABILITY - LATAM revenue matched prior-year's strong Q3, as expanded product portfolio and new markets offset high one-time orders in 2025


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

EUR 3.30 mln


Analyst Coverage

  • The one available analyst rating on the shares is "buy"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Aap Implantate AG is €1.68, about 19.1% above its November 9 closing price of €1.41


Reuters Recommended Reads

  • Nov 9 - Orthofix Medical Q3 revenue misses; cuts full-year guidance due to weaker US Spine performance

  • Nov 9 - OraSure Technologies Q3 revenue rises, gross margin improves

  • Nov 9 - Oncology firm Delcath Systems' Q3 revenue beats on Hepzato growth


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.